Table 4.

Adverse Events by Treatment Group

N (%)	Dimdazenil (n = 367)	Placebo (n = 178)	P-value
TEAE	174 (47.41)	71 (39.89)	0.100
Serious TEAE	2 (0.54)	2 (1.12)	0.600
Reduction of platelet count	1 (0.27)	0 (0.00)
Rib fracture	0 (0.00)	1 (0.56)
Diabetic foot	1 (0.27)	0 (0.00)
Spontaneous abortion	0 (0.00)	1 (0.56)
TEAE rate more than 2% in any group
Hyperuricemia	3 (0.82)	4 (2.25)	0.472
Vertigo	11 (3.00)	5 (2.81)	1.000
Headache	16 (4.36)	4 (2.25)	0.331
Dizzy	46 (12.53)	9 (5.06)	0.006
Ocular hypertension	10 (2.72)	7 (3.93)	0.441
TRAE	110 (29.97)	39 (21.91)	0.052
TRAE rate of more than 2% in any group
Vertigo	10 (2.72)	5 (2.81)	1.000
Dizzy	36 (9.81)	8 (4.49)	0.043
Ocular hypertension	9 (2.45)	7 (3.93)	0.417

TEAE, treatment emerged adverse event; TRAE, treatment-related adverse event.